TScan Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TCRX Nasdaq 2830 www.tscan.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TScan Therapeutics, Inc.

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal - Sep 4th, 2026 3:00 am
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program - Sep 2nd, 2026 6:30 am
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors - Sep 2nd, 2026 5:00 am
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership? - Aug 26th, 2026 1:08 pm
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Aug 12th, 2026 6:10 am
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 12th, 2026 5:00 am
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates - Aug 6th, 2026 7:50 am
Cell and gene therapy manufacturers turn to specialist automation partners - Jul 31st, 2026 4:17 am
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies - Jul 29th, 2026 5:00 am
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Jun 24th, 2026 5:00 am
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Jun 22nd, 2026 5:00 am
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Jun 3rd, 2026 7:19 am
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Jun 2nd, 2026 7:57 am
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - May 6th, 2026 6:25 am
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 6th, 2026 5:00 am
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting - Apr 27th, 2026 2:30 pm
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Apr 8th, 2026 5:00 am
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Mar 25th, 2026 1:35 pm
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Mar 4th, 2026 6:15 am